CD38 and prostate carcinoma: To further investigate the methylation status of CD38 in prostate cancer cell lines and clinical specimens, we used a previously described and extensively validated combined methylation-sensitive restriction enzyme digestion and methylated-DNA precipitation assay (COMPARE-MS) [38, 58, 59].